Description
Global Hemodynamic Monitoring System Market Forecast
Market Overview
Global Hemodynamic Monitoring System Market is anticipated to exhibit a healthy CAGR of 6.48% during the forecast period of 2020 to 2027. The global market is primarily attributed to the rising number of critically ill geriatric cases, increasing prevalence of cardiovascular disorders & diabetes, growing demand for home-based and non-invasive monitoring systems, and technological evolution in the hemodynamic monitoring system.
The global hemodynamic monitoring system is expected to witness a notable market owing to the highest value of USD 1,265.60 Million in 2019. Moreover, many major market players focus more on making these hemodynamic monitoring systems technologically expanded to meet the growing product demand through mergers and acquisitions, and product launches.
The growth of technologically advanced minimally invasive or non-invasive products for the hemodynamic monitoring system has raised its sales in-home care settings and clinics.
Market Segmentation
Global Hemodynamic Monitoring System Market has been segmented into Type, Product, and End User.
In terms of type segment, the global market has been classified into invasive, minimally invasive, and non-invasive hemodynamic monitoring systems. The non-invasive hemodynamic monitoring system segment is expected to register the highest CAGR of 7.73% during the forecast period.
By product type, the market has been divided into hemodynamic monitoring systems and disposables.
The disposables segment was valued at USD 786.75 million in 2019. The segment is expected to dominate the market due to the rising demand for disposables used for the diagnosis and treatment of critically ill patients.
Based on the end-user segment, the hemodynamic monitoring system market has been classified into hospitals & clinics, ambulatory care centers, and others. The hospitals and clinics segment is expected to dominate the market owing to the growing number of hospitals and clinics and the rapid adoption of advanced technologies in many clinics.
Regional Analysis
The region-specific analysis of the Global Hemodynamic Monitoring System Market has been studied across the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is likely to lead the market owing to the rising prevalence of cardiovascular diseases & diabetes, product launch, and acquisition in this region.
Europe contributed a substantial share of 29.8% in the global market owing to the companies’ organic growth strategies and a well-developed medical industry in the region. Asia-Pacific is expected to register a fastest-growing market owing to the high incidence of cardiovascular diseases, COPD, and diabetes.
The hemodynamic monitoring system market in Middle East & Africa is anticipated to register a limited growth during the forecast period owing to the increasing prevalence of cardiac disorders and diabetes, rising in the number of critically ill geriatric cases, advancements in technology, funding by private players and government bodies, the growing demand for home-based and non-invasive monitoring systems, and the increasing number of people suffering from hypertension.
Major Players
The Prominent players in the global hemodynamic monitoring system market are Edwards Lifesciences Corporation, Getinge AB, Baxter International Inc., Drägerwerk AG & Co. KGaA, LiDCO Group, Osypka Medical GmbH, Deltex Medical, ICU Medical, CNSYSTEMS MEDIZINTECHNIK GMBH, and NI Medical.
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries.
Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
Global Hemodynamic Monitoring Devices Market: Focus on Product, Modality, Setting, and 21 Countries & Analysis and Forecast, 2021-2030
Table of Contents
TABLE OF CONTENT
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY 16
2.2 RESEARCH OBJECTIVE 16
2.3 MARKET STRUCTURE 16
2.4 ASSUMPTIONS & LIMITATIONS 17
3 RESEARCH METHODOLOGY
3.1 DATA MINING 18
3.2 SECONDARY RESEARCH 19
3.3 PRIMARY RESEARCH 20
3.4 BREAKDOWN OF PRIMARY RESPONDENTS 21
3.5 FORECASTING TECHNIQUES 21
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 22
3.6.1 BOTTOM-UP APPROACH 24
3.6.2 TOP-DOWN APPROACH 24
3.7 DATA TRIANGULATION 25
3.8 VALIDATION 25
4 MARKET DYNAMICS
4.1 OVERVIEW 26
4.2 DRIVERS 27
4.2.1 INCREASING PREVALENCE OF CARDIOVASCULAR DISEASE AND LIFESTYLE RELATED DISEASES 27
4.2.2 RISING DEMAND FOR MINIMALLY INVASIVE HEMODYNAMIC MONITORING SYSTEM 27
4.2.3 TECHNOLOGICAL ADVANCEMENTS IN HEMODYNAMICS MONITORING SYSTEM 27
4.2.4 FAVORABLE GOVERNMENT INITIATIVES TO CREATE AWARENESS ABOUT CARDIOVASCULAR DISEASES 28
4.3 RESTRAINTS 28
4.3.1 RISKS ASSOCIATED WITH HEMODYNAMIC MONITORING SYSTEM 28
4.4 OPPORTUNITY 29
4.4.1 EMERGING MARKET PLAYERS IN THE HEMODYNAMIC MONITORING SYSTEM 29
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS 30
5.1.1 R&D AND DESIGNING 31
5.1.2 MANUFACTURING 31
5.1.3 DISTRIBUTION & SALES 31
5.1.4 POST-SALES MONITORING 31
5.2 PORTER’S FIVE FORCES MODEL 32
5.2.1 BARGAINING POWER OF SUPPLIERS 32
5.2.2 BARGAINING POWER OF BUYERS 33
5.2.3 THREAT OF NEW ENTRANTS 33
5.2.4 THREAT OF SUBSTITUTES 33
5.2.5 INTENSITY OF RIVALRY 33
5.3 COVID-19 IMPACT ANALYSIS 34
5.3.1 DEMAND SUPPLY ANALYSIS 34
5.3.2 IMPACT ON MAJOR REGIONS (AMERICAS, EUROPE, ASIA-PACIFIC, AND THE MIDDLE EAST & AFRICA) 34
5.3.3 IMPACT ON KEY PLAYERS 35
6 GLOBAL HEMODYNAMIC MONITORING SYSTEMS MARKET, BY TYPE
6.1 OVERVIEW 36
6.2 INVASIVE HEMODYNAMIC MONITORING SYSTEM 37
6.3 MINIMALLY INVASIVE HEMODYNAMIC MONITORING SYSTEM 38
6.4 NON-INVASIVE HEMODYNAMIC MONITORING SYSTEM 38
7 GLOBAL HEMODYNAMIC MONITORING SYSTEMS MARKET, BY PRODUCT
7.1 OVERVIEW 40
7.2 HEMODYNAMIC MONITORING SYSTEMS 41
7.3 DISPOSABLES 42
8 GLOBAL HEMODYNAMIC MONITORING SYSTEMS MARKET, BY END USER
8.1 OVERVIEW 43
8.2 HOSPITALS & CLINICS 44
8.3 AMBULATORY CARE CENTERS 44
8.4 OTHERS 45
9 GLOBAL HEMODYNAMIC MONITORING SYSTEMS MARKET, BY REGION
9.1 OVERVIEW 46
9.2 AMERICAS 48
9.2.1 NORTH AMERICA 50
9.2.1.1 US 52
9.2.1.2 CANADA 54
9.2.2 LATIN AMERICA 56
9.3 EUROPE 58
9.3.1 WESTERN EUROPE 60
9.3.1.1 GERMANY 62
9.3.1.2 FRANCE 64
9.3.1.3 UK 66
9.3.1.4 ITALY 67
9.3.1.5 SPAIN 69
9.3.1.6 REST OF WESTERN EUROPE 71
9.3.2 EASTERN EUROPE 72
9.4 ASIA-PACIFIC 75
9.4.1 JAPAN 78
9.4.2 CHINA 79
9.4.3 INDIA 81
9.4.4 AUSTRALIA 83
9.4.5 SOUTH KOREA 84
9.4.6 REST OF ASIA-PACIFIC 86
9.5 MIDDLE EAST & AFRICA 88
9.5.1 MIDDLE EAST 90
9.5.2 AFRICA 92
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW 94
10.2 COMPETITIVE BENCHMARKING 96
10.3 COMPETITOR DASHBOARD 97
10.4 MAJOR GROWTH STRATEGY IN THE GLOBAL HEMODYNAMIC MONITORING DEVICES MARKET 98
10.5 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL HEMODYNAMIC MONITORING DEVICES MARKET 99
10.6 KEY DEVELOPMENT ANALYSIS 99
10.7 KEY DEVELOPMENTS & GROWTH STRATEGIES 100
10.7.1 PRODUCT LAUNCH/PRODUCT APPROVAL 100
10.7.2 MERGERS/ACQUISITIONS 101
10.7.3 PARTNERSHIPS/AGREEMENTS 102
11 COMPANY PROFILES
11.1 EDWARDS LIFESCIENCES CORPORATION 103
11.1.1 COMPANY OVERVIEW 103
11.1.2 FINANCIAL OVERVIEW 104
11.1.3 PRODUCTS/SERVICES OFFERED 104
11.1.4 KEY DEVELOPMENTS 105
11.1.5 SWOT ANALYSIS 106
11.1.6 KEY STRATEGIES 107
11.2 GETINGE AB 108
11.2.1 COMPANY OVERVIEW 108
11.2.2 FINANCIAL OVERVIEW 108
11.2.3 PRODUCTS/SERVICES OFFERED 109
11.2.4 KEY DEVELOPMENTS 109
11.2.5 SWOT ANALYSIS 110
11.2.6 KEY STRATEGIES 110
11.3 BAXTER INTERNATIONAL INC. 111
11.3.1 COMPANY OVERVIEW 111
11.3.2 FINANCIAL OVERVIEW 111
11.3.3 PRODUCTS/SERVICES OFFERED 112
11.3.4 KEY DEVELOPMENTS 112
11.3.5 SWOT ANALYSIS 113
11.3.6 KEY STRATEGIES 113
11.4 DRÄGERWERK AG & CO. KGAA 114
11.4.1 COMPANY OVERVIEW 114
11.4.2 FINANCIAL OVERVIEW 114
11.4.3 PRODUCTS/SERVICES OFFERED 115
11.4.4 KEY DEVELOPMENTS 115
11.4.5 SWOT ANALYSIS 116
11.4.6 KEY STRATEGIES 116
11.5 LIDCO GROUP 117
11.5.1 COMPANY OVERVIEW 117
11.5.2 FINANCIAL OVERVIEW 117
11.5.3 PRODUCTS/SERVICES OFFERED 118
11.5.4 KEY DEVELOPMENTS 118
11.5.5 SWOT ANALYSIS 119
11.5.6 KEY STRATEGIES 119
11.6 OSYPKA MEDICAL GMBH 120
11.6.1 COMPANY OVERVIEW 120
11.6.2 FINANCIAL OVERVIEW 120
11.6.3 PRODUCTS/SERVICES OFFERED 120
11.6.4 KEY DEVELOPMENTS 120
11.6.5 SWOT ANALYSIS 121
11.6.6 KEY STRATEGIES 121
11.7 DELTEX MEDICAL 122
11.7.1 COMPANY OVERVIEW 122
11.7.2 FINANCIAL OVERVIEW 122
11.7.3 PRODUCTS/SERVICES OFFERED 122
11.7.4 KEY DEVELOPMENTS 123
11.7.5 SWOT ANALYSIS 124
11.7.6 KEY STRATEGIES 124
11.8 ICU MEDICAL 125
11.8.1 COMPANY OVERVIEW 125
11.8.2 FINANCIAL OVERVIEW 125
11.8.3 PRODUCTS/SERVICES OFFERED 126
11.8.4 KEY DEVELOPMENTS 126
11.8.5 SWOT ANALYSIS 126
11.8.6 KEY STRATEGIES 126
11.9 CNSYSTEMS MEDIZINTECHNIK GMBH 127
11.9.1 COMPANY OVERVIEW 127
11.9.2 FINANCIAL OVERVIEW 127
11.9.3 PRODUCTS/SERVICES OFFERED 127
11.9.4 KEY DEVELOPMENTS 127
11.9.5 SWOT ANALYSIS 128
11.9.6 KEY STRATEGIES 128
11.10 NI MEDICAL 129
11.10.1 COMPANY OVERVIEW 129
11.10.2 FINANCIAL OVERVIEW 129
11.10.3 PRODUCTS/SERVICES OFFERED 129
11.10.4 KEY DEVELOPMENTS 129
11.10.5 SWOT ANALYSIS 130
11.10.6 KEY STRATEGIES 130
12 APPENDIX
12.1 REFERENCES 131
12.2 RELATED REPORTS 131
